---
title: "Mylan Laboratories Ltd (MATRIXLABS) — Share Price, Financials & Analysis"
symbol: "MATRIXLABS"
company: "Mylan Laboratories Ltd"
canonical: "https://tapetide.com/stocks/MATRIXLABS"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:15:40.352Z"
---

# Mylan Laboratories Ltd (MATRIXLABS)

Canonical page: https://tapetide.com/stocks/MATRIXLABS

## Company

- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹2
- **F&O Eligible:** No

## About

Mylan Laboratories Limited,incorporated in India, listed on the Bombay Stock Exchange Limited,  the company is engaged in the manufacture and trading of Pharmaceuticals

## Latest Price

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 9.47% over past five years.
- Company has a low return on equity of -5.06% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | -19% | 0% | — |
| revenue growth | 14% | 5% | 9% |

## Financial Statements

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1882 | 2878 | 3952 | 5392 | 6978 | 7857 | 9467 | 9623 | 9638 | 10969 |
| Expenses | 1611 | 2342 | 3177 | 4392 | 6100 | 7293 | 8485 | 8079 | 7811 | 9219 |
| Operating Profit | 271 | 536 | 776 | 1000 | 878 | 564 | 982 | 1544 | 1827 | 1750 |
| OPM % | 14 | 19 | 20 | 19 | 13 | 7 | 10 | 16 | 19 | 16 |
| Other Income | 129 | 185 | 28 | 12 | 843 | 923 | 619 | 357 | 505 | 296 |
| Interest | 54 | 43 | 58 | 63 | 248 | 569 | 716 | 857 | 817 | 828 |
| Depreciation | 46 | 60 | 78 | 96 | 346 | 852 | 1191 | 1681 | 1806 | 1567 |
| Profit before tax | 299 | 617 | 668 | 853 | 1127 | 67 | -306 | -637 | -291 | -349 |
| Tax % | 29 | 25 | 30 | 39 | 25 | -99 | -56 | -26 | 14 | 17 |
| Net Profit | 214 | 466 | 469 | 520 | 845 | 134 | -135 | -470 | -331 | -408 |
| EPS in Rs | 13.68 | 29.79 | 30.01 | 33.23 | 54.04 | 8.59 | -8.62 | -30.03 | -21.16 | -26.11 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 31 | 31 | 31 | 31 | 37 | 38 | 49 | 49 | 49 | 49 |
| Reserves | 1121 | 1602 | 1822 | 2455 | 4142 | 4675 | 6777 | 8064 | 7646 | 7126 |
| Borrowings | 612 | 836 | 1212 | 1800 | 6627 | 6974 | 10950 | 9283 | 8555 | 8582 |
| Other Liabilities | 697 | 1132 | 1526 | 1769 | 3583 | 3130 | 3331 | 2758 | 3146 | 3405 |
| Total Liabilities | 2461 | 3601 | 4592 | 6057 | 14389 | 14817 | 21106 | 20154 | 19395 | 19162 |
| Fixed Assets | 858 | 1153 | 1355 | 1800 | 6220 | 6010 | 10809 | 10138 | 9076 | 7948 |
| CWIP | 133 | 77 | 110 | 131 | 1021 | 941 | 805 | 762 | 367 | 328 |
| Investments | 177 | 262 | 245 | 54 | 156 | 163 | 0 | 0 | 0 | 0 |
| Other Assets | 1292 | 2108 | 2882 | 4072 | 6992 | 7703 | 9492 | 9254 | 9953 | 10886 |
| Total Assets | 2461 | 3601 | 4592 | 6057 | 14389 | 14817 | 21106 | 20154 | 19395 | 19162 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 229 | 139 | 50 | 351 | 384 | 679 | 256 | 1605 | 2101 | 1325 |
| Cash from Investing Activity | -174 | -331 | -341 | -835 | -5761 | -469 | -5794 | -569 | -632 | -372 |
| Cash from Financing Activity | -48 | 198 | 280 | 524 | 5420 | -280 | 5553 | -967 | -1554 | -960 |
| Net Cash Flow | 7 | 6 | -11 | 40 | 44 | -70 | 16 | 70 | -85 | -8 |
| Free Cash Flow | -63 | -193 | -296 | -267 | -148 | 93 | -460 | 673 | 1590 | 966 |
| CFO/OP | 113 | 53 | 25 | 65 | 77 | 132 | 29 | 105 | 116 | 76 |

### Ratios

| Item | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 94 | 71 | 97 | 86 | 118 | 99 | 121 | 137 | 137 | 122 |
| Inventory Days | 252 | 253 | 229 | 223 | 243 | 289 | 289 | 267 | 311 | 311 |
| Days Payable | 142 | 155 | 151 | 144 | 159 | 150 | 140 | 121 | 167 | 156 |
| Cash Conversion Cycle | 205 | 169 | 175 | 164 | 203 | 239 | 270 | 283 | 281 | 278 |
| Working Capital Days | 132 | 131 | 133 | 145 | 165 | 207 | 226 | 235 | 245 | 235 |
| ROCE % | 18 | 27 | 27 | 30 | 14 | 2 | 1 | 2 | 3 | 3 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 4 / 3 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 36.33 | Sell |
| EMA (10) | 35.26 | Sell |
| SMA (20) | 35.46 | Sell |
| EMA (20) | 36.04 | Sell |
| SMA (50) | 39.22 | Sell |
| EMA (50) | 37.69 | Sell |
| SMA (100) | 38.71 | Sell |
| EMA (100) | 39.01 | Sell |
| SMA (200) | 40.87 | Sell |
| EMA (200) | 41.38 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 40.72 | Neutral |
| MACD (12,26,9) | -1.01 | Sell |
| Stochastic (14,3,3) | 16.53 | Buy |
| ADX (14) | 54.01 | Buy |
| Williams %R (14) | -100 | Buy |
| ATR (14) | 4.41 | High Volatility |
| ROC (12) | -6.06 | Sell |
| Stoch RSI (14) | 10.35 | Buy |
| UO (7,14,28) | 37.94 | Neutral |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:15:40.352Z.